Horizon Therapeutics Public (NASDAQ:HZNP) PT Raised to $110.00 at Piper Sandler

Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) had its target price upped by analysts at Piper Sandler from $90.00 to $110.00 in a research report issued on Wednesday, The Fly reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Sandler’s price objective would suggest a potential upside of 13.51% from […]

Related Keywords

Piper Sandler ,Jefferies Financial Group ,Corecap Advisors ,Samalin Investment Counsel ,Steward Financial Group ,Horizon Therapeutics Public Limited Company ,Horizon Therapeutics Public ,Get Rating ,Financial Group ,Therapeutics Public ,Horizon Therapeutics ,Investment Counsel ,Cap Advisors ,Allworth Financial ,Therapeutics Public Limited Company ,Horizon Therapeutics Public Daily ,Nasdaq Hznp ,Hznp ,Medical ,44047t10 ,Boost Price Target ,